The European response to control and manage multi- And extensively drug-resistant Neisseria gonorrhoeae

, the European Gonorrhoea Response Plan Group; European Gonorrhoea Response Plan Group

doi:10.2807/1560-7917.ES.2022.27.18.2100611

The European response to control and manage multi- And extensively drug-resistant Neisseria gonorrhoeae

, the European Gonorrhoea Response Plan Group, European Gonorrhoea Response Plan Group

UK Health Security Agency

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Because cefixime and ceftriaxone resistance in Neisseria gonorrhoeae and gonorrhoea treatment failures were increasing, a response plan to control and manage multidrug-resistant N. gonorrhoeae (MDR-NG) in Europe was published in 2012. The three main areas of the plan were to: (i) strengthen surveillance of antimicrobial resistance (AMR), (ii) implement monitoring of treatment failures and (iii) establish a communication strategy to increase awareness and disseminate AMR results. Since 2012, several additional extensively drug-resistant N. gonorrhoeae (XDR-NG) strains have emerged, and strains with high-level ceftriaxone resistance spread internationally. This prompted an evaluation and review of the 2012 European Centre for Disease Prevention and Control (ECDC) response plan, revealing an overall improvement in many aspects of monitoring AMR in N. gonorrhoeae; however, treatment failure monitoring was a weakness. Accordingly, the plan was updated in 2019 to further support European Union/European Economic Area (EU/EEA) countries in controlling and managing the threat of MDR/XDR-NG in Europe through further strengthening of AMR surveillance and clinical management including treatment failure monitoring. The plan will be assessed biennially to ensure its effectiveness and its value. Along with prevention, diagnostic, treatment and epidemiological surveillance strategies, AMR surveillance is essential for effective control of gonorrhoea.

Original language	English
Article number	2100611
Journal	Eurosurveillance
Volume	27
Issue number	18
DOIs	https://doi.org/10.2807/1560-7917.ES.2022.27.18.2100611
Publication status	Published - 5 May 2022

Bibliographical note

Funding Information:
We are very grateful to all the Euro-GASP collaborators for their ongoing participation. We would particularly like to acknowledge the following collaborators for providing the indicator data: Tatjana Nemeth Blažić, Blaženka Hunjak (Croatia), Steen Hoffmann, Susan Cowan (Denmark), Jevgenia Epštein, Jelena Viktorova (Estonia), Panagiota Maikanti-Charalampous (Cyprus), Jari Jalava (Finland), Inga Velicko, Magnus Unemo (Sweden), Klaus Jansen (Germany), Irena Klavs, Samo Jeverica (Slovenia), Irith de Baetselier (Belgium), Eszter Balla (Hungary), Guðrún Sigmundsdóttir, Guðrún Svanborg Hauksdóttir, Lena Ros Asmundsdottir (Iceland), Violeta Mavcutko (Latvia), Monique Perrin (Luxembourg), Jackie Melillo (Malta), Alexander Indra, Sonja Pleininger, Steliana Huhlescu (Austria), Birgit van Benthem (The Netherlands), Hilde Kløvstad (Norway), Maria José Borrego (Portugal), Marina Jamnicki (Liechtenstein), Peter Pavlik, Peter Truska (Slovakia), Denisa Janta (Romania), Kate Templeton, Helen Fifer, Gwenda Hughes, Michelle Cole (UK). Many thanks to Benjamin Bluemel, Marieke van der Werf and Karl Ekdahl at ECDC for their expert review of the manuscript. The work was funded by the European Centre for Disease Prevention and Control (Framework Contract No. ECDC/2013/015).

Funding Information:
The work was funded by the European Centre for Disease Prevention and Control (Framework Contract No. ECDC/2013/015).

Publisher Copyright:
© 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2807/1560-7917.ES.2022.27.18.2100611

Cite this

@article{ff81582c0a6d499e94103dde5827780c,

title = "The European response to control and manage multi- And extensively drug-resistant Neisseria gonorrhoeae",

abstract = "Because cefixime and ceftriaxone resistance in Neisseria gonorrhoeae and gonorrhoea treatment failures were increasing, a response plan to control and manage multidrug-resistant N. gonorrhoeae (MDR-NG) in Europe was published in 2012. The three main areas of the plan were to: (i) strengthen surveillance of antimicrobial resistance (AMR), (ii) implement monitoring of treatment failures and (iii) establish a communication strategy to increase awareness and disseminate AMR results. Since 2012, several additional extensively drug-resistant N. gonorrhoeae (XDR-NG) strains have emerged, and strains with high-level ceftriaxone resistance spread internationally. This prompted an evaluation and review of the 2012 European Centre for Disease Prevention and Control (ECDC) response plan, revealing an overall improvement in many aspects of monitoring AMR in N. gonorrhoeae; however, treatment failure monitoring was a weakness. Accordingly, the plan was updated in 2019 to further support European Union/European Economic Area (EU/EEA) countries in controlling and managing the threat of MDR/XDR-NG in Europe through further strengthening of AMR surveillance and clinical management including treatment failure monitoring. The plan will be assessed biennially to ensure its effectiveness and its value. Along with prevention, diagnostic, treatment and epidemiological surveillance strategies, AMR surveillance is essential for effective control of gonorrhoea.",

author = "{, the European Gonorrhoea Response Plan Group} and {European Gonorrhoea Response Plan Group} and Cole, {Michelle J.} and Michaela Day and Susanne Jacobsson and Amato-Gauci, {Andrew J.} and Gianfranco Spiteri and Magnus Unemo",

note = "Funding Information: We are very grateful to all the Euro-GASP collaborators for their ongoing participation. We would particularly like to acknowledge the following collaborators for providing the indicator data: Tatjana Nemeth Bla{\v z}i{\'c}, Bla{\v z}enka Hunjak (Croatia), Steen Hoffmann, Susan Cowan (Denmark), Jevgenia Ep{\v s}tein, Jelena Viktorova (Estonia), Panagiota Maikanti-Charalampous (Cyprus), Jari Jalava (Finland), Inga Velicko, Magnus Unemo (Sweden), Klaus Jansen (Germany), Irena Klavs, Samo Jeverica (Slovenia), Irith de Baetselier (Belgium), Eszter Balla (Hungary), Gu{\dh}r{\'u}n Sigmundsd{\'o}ttir, Gu{\dh}r{\'u}n Svanborg Hauksd{\'o}ttir, Lena Ros Asmundsdottir (Iceland), Violeta Mavcutko (Latvia), Monique Perrin (Luxembourg), Jackie Melillo (Malta), Alexander Indra, Sonja Pleininger, Steliana Huhlescu (Austria), Birgit van Benthem (The Netherlands), Hilde Kl{\o}vstad (Norway), Maria Jos{\'e} Borrego (Portugal), Marina Jamnicki (Liechtenstein), Peter Pavlik, Peter Truska (Slovakia), Denisa Janta (Romania), Kate Templeton, Helen Fifer, Gwenda Hughes, Michelle Cole (UK). Many thanks to Benjamin Bluemel, Marieke van der Werf and Karl Ekdahl at ECDC for their expert review of the manuscript. The work was funded by the European Centre for Disease Prevention and Control (Framework Contract No. ECDC/2013/015). Funding Information: The work was funded by the European Centre for Disease Prevention and Control (Framework Contract No. ECDC/2013/015). Publisher Copyright: {\textcopyright} 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.",

year = "2022",

month = may,

day = "5",

doi = "10.2807/1560-7917.ES.2022.27.18.2100611",

language = "English",

volume = "27",

journal = "Eurosurveillance",

issn = "1025-496X",

publisher = "European Centre for Disease Prevention and Control",

number = "18",

}

TY - JOUR

T1 - The European response to control and manage multi- And extensively drug-resistant Neisseria gonorrhoeae

AU - , the European Gonorrhoea Response Plan Group

AU - European Gonorrhoea Response Plan Group

AU - Cole, Michelle J.

AU - Day, Michaela

AU - Jacobsson, Susanne

AU - Amato-Gauci, Andrew J.

AU - Spiteri, Gianfranco

AU - Unemo, Magnus

N1 - Funding Information: We are very grateful to all the Euro-GASP collaborators for their ongoing participation. We would particularly like to acknowledge the following collaborators for providing the indicator data: Tatjana Nemeth Blažić, Blaženka Hunjak (Croatia), Steen Hoffmann, Susan Cowan (Denmark), Jevgenia Epštein, Jelena Viktorova (Estonia), Panagiota Maikanti-Charalampous (Cyprus), Jari Jalava (Finland), Inga Velicko, Magnus Unemo (Sweden), Klaus Jansen (Germany), Irena Klavs, Samo Jeverica (Slovenia), Irith de Baetselier (Belgium), Eszter Balla (Hungary), Guðrún Sigmundsdóttir, Guðrún Svanborg Hauksdóttir, Lena Ros Asmundsdottir (Iceland), Violeta Mavcutko (Latvia), Monique Perrin (Luxembourg), Jackie Melillo (Malta), Alexander Indra, Sonja Pleininger, Steliana Huhlescu (Austria), Birgit van Benthem (The Netherlands), Hilde Kløvstad (Norway), Maria José Borrego (Portugal), Marina Jamnicki (Liechtenstein), Peter Pavlik, Peter Truska (Slovakia), Denisa Janta (Romania), Kate Templeton, Helen Fifer, Gwenda Hughes, Michelle Cole (UK). Many thanks to Benjamin Bluemel, Marieke van der Werf and Karl Ekdahl at ECDC for their expert review of the manuscript. The work was funded by the European Centre for Disease Prevention and Control (Framework Contract No. ECDC/2013/015). Funding Information: The work was funded by the European Centre for Disease Prevention and Control (Framework Contract No. ECDC/2013/015). Publisher Copyright: © 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.

PY - 2022/5/5

Y1 - 2022/5/5

N2 - Because cefixime and ceftriaxone resistance in Neisseria gonorrhoeae and gonorrhoea treatment failures were increasing, a response plan to control and manage multidrug-resistant N. gonorrhoeae (MDR-NG) in Europe was published in 2012. The three main areas of the plan were to: (i) strengthen surveillance of antimicrobial resistance (AMR), (ii) implement monitoring of treatment failures and (iii) establish a communication strategy to increase awareness and disseminate AMR results. Since 2012, several additional extensively drug-resistant N. gonorrhoeae (XDR-NG) strains have emerged, and strains with high-level ceftriaxone resistance spread internationally. This prompted an evaluation and review of the 2012 European Centre for Disease Prevention and Control (ECDC) response plan, revealing an overall improvement in many aspects of monitoring AMR in N. gonorrhoeae; however, treatment failure monitoring was a weakness. Accordingly, the plan was updated in 2019 to further support European Union/European Economic Area (EU/EEA) countries in controlling and managing the threat of MDR/XDR-NG in Europe through further strengthening of AMR surveillance and clinical management including treatment failure monitoring. The plan will be assessed biennially to ensure its effectiveness and its value. Along with prevention, diagnostic, treatment and epidemiological surveillance strategies, AMR surveillance is essential for effective control of gonorrhoea.

AB - Because cefixime and ceftriaxone resistance in Neisseria gonorrhoeae and gonorrhoea treatment failures were increasing, a response plan to control and manage multidrug-resistant N. gonorrhoeae (MDR-NG) in Europe was published in 2012. The three main areas of the plan were to: (i) strengthen surveillance of antimicrobial resistance (AMR), (ii) implement monitoring of treatment failures and (iii) establish a communication strategy to increase awareness and disseminate AMR results. Since 2012, several additional extensively drug-resistant N. gonorrhoeae (XDR-NG) strains have emerged, and strains with high-level ceftriaxone resistance spread internationally. This prompted an evaluation and review of the 2012 European Centre for Disease Prevention and Control (ECDC) response plan, revealing an overall improvement in many aspects of monitoring AMR in N. gonorrhoeae; however, treatment failure monitoring was a weakness. Accordingly, the plan was updated in 2019 to further support European Union/European Economic Area (EU/EEA) countries in controlling and managing the threat of MDR/XDR-NG in Europe through further strengthening of AMR surveillance and clinical management including treatment failure monitoring. The plan will be assessed biennially to ensure its effectiveness and its value. Along with prevention, diagnostic, treatment and epidemiological surveillance strategies, AMR surveillance is essential for effective control of gonorrhoea.

UR - http://www.scopus.com/inward/record.url?scp=85129438353&partnerID=8YFLogxK

U2 - 10.2807/1560-7917.ES.2022.27.18.2100611

DO - 10.2807/1560-7917.ES.2022.27.18.2100611

M3 - Article

C2 - 35514307

AN - SCOPUS:85129438353

SN - 1025-496X

VL - 27

JO - Eurosurveillance

JF - Eurosurveillance

IS - 18

M1 - 2100611

ER -

The European response to control and manage multi- And extensively drug-resistant Neisseria gonorrhoeae

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this